Physician profile
Ryan G Planer
NPI 1194106096
$3,417.91
in general payments reported to CMS, 2019-2025
46 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.39 · 2021: $323 · 2022: $420 · 2023: $660 · 2024: $908 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $277.46 | 2022-2025 | Emgality, Jardiance, Mounjaro |
| Abbvie INC. | $264.48 | 2021-2025 | |
| Pfizer INC. | $257.71 | 2022-2025 | |
| Novo Nordisk INC | $250.60 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.58 | 2021-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Amgen INC. | $171.59 | 2021-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $158.95 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $149.23 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $138.37 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $126.22 | 2023-2025 | |
| Ucb, INC. | $88.61 | 2021-2025 | Nayzilam, Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $82.82 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $80.49 | 2022-2024 | Xarelto |
| Genentech USA, INC. | $71.58 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.14 | 2021-2023 | Trulance, Xifaxan |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $65.18 | 2024-2025 | Vyepti, Rexulti |
| Edwards Lifesciences Corporation | $60.87 | 2024-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $59.66 | 2021-2023 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $59.35 | 2023-2024 | Rexulti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.21 | 2023-2025 | Lifevest |
| Abbott Laboratories | $55.25 | 2024-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $53.16 | 2024-2025 | Omnipod |
| Exact Sciences Corporation | $48.74 | 2023-2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $45.00 | 2024-2025 | Ultomiris |
| Scpharmaceuticals INC. | $39.16 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $38.37 | 2023-2024 | Austedo Xr, Austedo |
| Indivior INC. | $30.32 | 2025 | Sublocade |
| Neurocrine Biosciences, INC. | $27.63 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $26.33 | 2025 | Uptravi, Opsumit |
| Abiomed | $25.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $24.38 | 2022 | |
| Alk-Abello, INC | $22.95 | 2024 | Grastek, Ragwitek, Odactra |
| Corium, LLC | $22.80 | 2025 | Azstarys |
| Corcept Therapeutics | $21.98 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.51 | 2025 | Caplyta |
| Emd Serono, INC. | $21.38 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $20.92 | 2021 | |
| Gilead Sciences, INC. | $19.64 | 2024 | |
| Janssen Biotech, INC. | $18.61 | 2025 | |
| Merck Sharp & Dohme LLC | $17.98 | 2023 | Gardasil 9 |
| Inspire Medical Systems, INC. | $17.66 | 2025 | Inspire |
| Janssen Scientific Affairs, LLC | $17.50 | 2024 | Xarelto |
| Arbor Pharmaceuticals, INC. | $16.79 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $16.65 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $14.67 | 2025 | Attruby |
| Dynavax Technologies Corporation | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Planer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.